# Qulipta (atogepant) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/atogepant

> The FDA approved Qulipta (atogepant), sponsored by AbbVie Inc. (ABBV), on September 28, 2021.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Qulipta (atogepant) |
| Codes | AGN-241689 |
| Sponsor | AbbVie Inc. (ABBV) https://sec-api.dev/companies/abbv/catalysts |
| Indications | [Migraine](https://sec-api.dev/indications/migraine), Menstrual Migraine (MM), [Chronic Migraine](https://sec-api.dev/indications/chronic-migraine), [Episodic Migraine](https://sec-api.dev/indications/episodic-migraine) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### September 28, 2021: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215206 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20210928, review_priority PRIORITY; sponsor_name ABBVIE; product QULIPTA (ATOGEPANT)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215206%22

### April 17, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215206 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20230417, review_priority STANDARD; sponsor_name ABBVIE; product QULIPTA (ATOGEPANT)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215206%22

### May 2, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Chronic Migraine.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05216263 (Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-02 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-06-16." https://clinicaltrials.gov/study/NCT05216263

### July 7, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Migraine.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06241313 (Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-07 (ACTUAL); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT06241313

### October 20, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Episodic Migraine; Chronic Migraine.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04686136 (A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-20 (ACTUAL); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT04686136

### June 16, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Chronic Migraine.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05216263 (Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-02 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-06-16." https://clinicaltrials.gov/study/NCT05216263?tab=results

### June 29, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Menstrual Migraine (MM).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06806293 (Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-29 (ACTUAL); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT06806293

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Episodic Migraine.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05711394 (A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT05711394

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Episodic Migraine.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05711394 (A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT05711394

## Same indication

- [Erenumab dose 1](https://sec-api.dev/pdufa/erenumab) (AMGN)
- [Evo756, dose 1](https://sec-api.dev/pdufa/evo756) (EVMN)
- [AJOVY® (fremanezumab)](https://sec-api.dev/pdufa/fremanezumab) (TEVA)
- [Galcanezumab](https://sec-api.dev/pdufa/galcanezumab) (LLY)
- [Reyvow (lasmiditan succinate)](https://sec-api.dev/pdufa/lasmiditan) (LLY)
- [MEDI0618](https://sec-api.dev/pdufa/medi0618) (ABBV)
- [Nurtec Odt (rimegepant sulfate)](https://sec-api.dev/pdufa/rimegepant) (PFE)
- [Ubrelvy (ubrogepant)](https://sec-api.dev/pdufa/ubrogepant) (ABBV)
- [Zavzpret ® (zavegepant)](https://sec-api.dev/pdufa/zavegepant) (PFE)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/atogepant.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Qulipta (atogepant) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/atogepant

```bibtex
@misc{secapidev_pdufa_atogepant_20261116,
  title        = {Qulipta (atogepant) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/atogepant}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_atogepant_20261116","title":"Qulipta (atogepant) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/atogepant","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
